Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P31749 (
AKT
)
22,954
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
AKT
pathway is a fundamental signaling pathway that mediates multiple cellular processes, such as cell proliferation and survival, angiogenesis, and glucose metabolism. We recently reported that the immunophilin FKBP51 is a scaffolding protein that can enhance PHLPP-
AKT
interaction and facilitate PHLPP-mediated dephosphorylation of
AKT
at Ser473, negatively regulating
AKT
activation. However, the regulation of FKBP51-PHLPP-
AKT
pathway remains unclear. Here we report that a deubiquitinase,
USP49
, is a new regulator of the
AKT
pathway. Mechanistically,
USP49
deubiquitinates and stabilizes FKBP51, which in turn enhances PHLPP's capability to dephosphorylate
AKT
Furthermore,
USP49
inhibited pancreatic cancer cell proliferation and enhanced cellular response to gemcitabine in a FKBP51-
AKT
-dependent manner. Clinically, decreased expression of
USP49
in patients with pancreatic cancer was associated with decreased FKBP51 expression and increased
AKT
phosphorylation. Overall, our findings establish
USP49
as a novel regulator of
AKT
pathway with a critical role in tumorigenesis and chemo-response in pancreatic cancer.
...
PMID:USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. 2836 42